{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T20:10:04Z","timestamp":1752264604477,"version":"3.41.2"},"reference-count":16,"publisher":"ALUNA","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:p>Aim: To investigate hepcidin as a marker of iron status in chronic kidney disease (CKD) patients (stage 5 vs. stage 3), and to assess its association with iron injection status within the maintenance hemodialysis group.\nMaterials and Methods: This cross-sectional study compared 69 hemodialysis (stage 5 CKD [G1]) and 19 non-dialysis (stage 3 CKD [G2]) patients, assessing hepcidin, ferritin and hemoglobin. As a part of their standard anemia management, patients requiring iron administration received scheduled injections of ferric carboxymaltose.\nResults: Hemodialysis patients (G1) had significantly lower hemoglobin and higher anemia prevalence than non-dialysis patients (G2), while baseline hepcidin and ferritin levels were comparable. Importantly, hepcidin levels were above the normal range in 85,5% and 84,2% of G1 and G2 patients, respectively. Hepcidin correlated positively with ferritin in both groups (G1: \u03c1=0,66, p&lt;0,001; G2: \u03c1=0,87, p&lt;0,001). Within G1, recent iron injections, administered in 24 patients, were significantly associated with higher hepcidin and ferritin, but not hemoglobin, as compared to patients without additional ferric therapy (n=45) (effect size: r=0,09 [by hemoglobin], r=0,80 [by hepcidin] and r=0,58 [by ferritin]).\nConclusions: Significant iron metabolism impairment, marked by high hepcidin and ferritin prevalence, exists in both CKD stages studied. Although hemodialysis patients had lower hemoglobin, baseline hepcidin\/ferritin levels were similar between groups. Within the hemodialysis group, recent iron injections were associated with increased hepcidin\/ferritin but not hemoglobin. Findings suggest hepcidin may be a crucial indicator of functional iron availability in CKD, potentially offering more insight than ferritin, particularly reflecting acute changes following iron administration in hemodialysis patients.<\/jats:p>","DOI":"10.36740\/merkur202503113","type":"journal-article","created":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T19:45:18Z","timestamp":1752263118000},"page":"384-388","source":"Crossref","is-referenced-by-count":0,"title":["Hepcidin as a marker of iron status in patients with chronic kidney disease"],"prefix":"10.36740","volume":"53","author":[{"given":"Vladyslav O.","family":"Bardash","sequence":"first","affiliation":[{"name":"DANYLO HALYTSKY LVIV NATIONAL MEDICAL UNIVERSITY, LVIV, UKRAINE"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetiana A.","family":"Maksymets","sequence":"additional","affiliation":[{"name":"DANYLO HALYTSKY LVIV NATIONAL MEDICAL UNIVERSITY, LVIV, UKRAINE"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olha O.","family":"Bondarenko","sequence":"additional","affiliation":[{"name":"DANYLO HALYTSKY LVIV NATIONAL MEDICAL UNIVERSITY, LVIV, UKRAINE"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Halyna I.","family":"Kovalchuk","sequence":"additional","affiliation":[{"name":"DANYLO HALYTSKY LVIV NATIONAL MEDICAL UNIVERSITY, LVIV, UKRAINE"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zoryana M.","family":"Kit","sequence":"additional","affiliation":[{"name":"DANYLO HALYTSKY LVIV NATIONAL MEDICAL UNIVERSITY, LVIV, UKRAINE"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalia V.","family":"Karpyshyn","sequence":"additional","affiliation":[{"name":"DANYLO HALYTSKY LVIV NATIONAL MEDICAL UNIVERSITY, LVIV, UKRAINE"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugen Ya.","family":"Sklyarov","sequence":"additional","affiliation":[{"name":"DANYLO HALYTSKY LVIV NATIONAL MEDICAL UNIVERSITY, LVIV, UKRAINE"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"22436","published-online":{"date-parts":[[2025]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"1. Gafter-Gvili A, Schechter A, Rozen-Zvi B. Iron deficiency anemia in chronic kidney disease. Acta Haematol. 2019;142(1):44-50. doi: 10.1159\/000496492.","DOI":"10.1159\/000496492"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"2. Susantitaphong P, Alqahtani F, Jaber BL. Efficacy and safety of intravenous iron therapy for functional iron deficiency anemia in hemodialysis patients: a meta-analysis. Am J Nephrol. 2014;39(2):130\u2013141. doi: 10.1159\/000358336.","DOI":"10.1159\/000358336"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"3. Hentze MW, Muckenthaler MU, Galy B, Camaschella C. Two to tango: regulation of mammalian iron metabolism. Cell. 2010;142(1):24-38. doi: 10.1016\/j.cell.2010.06.028.","DOI":"10.1016\/j.cell.2010.06.028"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"4. Zhao N, Zhang AS, Enns CA. Iron regulation by hepcidin. J Clin Invest. 2013;123(6):2337-2343. doi: 10.1172\/JCI67225.","DOI":"10.1172\/jci67225"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"5. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024;105(4):S117-S314. doi: 10.1016\/j.kint.2023.10.018.","DOI":"10.1016\/j.kisu.2017.10.001"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"6. Troutt JS, Butterfield AM, Konrad RJ. Hepcidin-25 concentrations are markedly increased in patients with chronic kidney disease and are inversely correlated with estimated glomerular filtration rates. J Clin Lab Anal. 2013;27(6):504-510. doi: 10.1002\/jcla.21634.","DOI":"10.1002\/jcla.21634"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"7. Zaritsky J, Young B, Wang HJ et al. Hepcidin \u2013 a potential novel biomarker for iron status in chronic kidney disease. Clin J Am Soc Nephrol. 2009;4(6):1051\u20131056. doi: 10.2215\/CJN.05931108.","DOI":"10.2215\/cjn.05931108"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"8. Kumir A, Porwal YC, Kumar R, Yadav A. Correlation between serum hepcidin level and stages of chronic kidney disease: a cross sectional study. Open Access Research Journal of Multidisciplinary Studies. 2023;6:8-16. doi: 10.53022\/oarjms.2023.6.1.0032.","DOI":"10.53022\/oarjms.2023.6.1.0032"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"9. Ueda N, Takasawa K. Impact of inflammation on ferritin, hepcidin and the management of iron deficiency anemia in chronic kidney disease. Nutrients. 2018;10(9):1173. doi: 10.3390\/nu10091173.","DOI":"10.3390\/nu10091173"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"10. McDonnell T, Kalra PA. Iron in chronic kidney disease and end-stage kidney disease\u2013current trends and future direction. Br J Hosp Med (Lond). 2024;85(4):1-10. doi: 10.12968\/hmed.2023.0619.","DOI":"10.12968\/hmed.2024.0619"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"11. Indirajith V, Sivagnanam S, Rajappa R. Serum level of hepcidin in chronic kidney disease \u2013 a hospital-based study from South India. Asian J Med Sci. 2022;13(11):70-76. doi: 10.3126\/ajms.v13i11.48695.","DOI":"10.3126\/ajms.v13i11.48695"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"12. Badura K, Janc J, W\u0105sik J et al. Anemia of chronic kidney disease\u2013a narrative review of its pathophysiology, diagnosis, and management. Biomedicines. 2024;12(6):1191. doi: 10.3390\/biomedicines12061191.","DOI":"10.3390\/biomedicines12061191"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"13. Bek SG, Ustuner B, Eren N et al. The effect of hepcidin on components of metabolic syndrome in chronic kidney disease: a cross-sectional study. Rev Assoc Med Bras (1992). 2020;66(8):1100-1107. doi: 10.1590\/1806-9282.66.8.1100.","DOI":"10.1590\/1806-9282.66.8.1100"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"14. Nakanishi T, Kuragano T. Potential hazards of recent trends in liberal iron use for renal anemia. Clin Kidney J. 2021;14(1):i59-i69. doi: 10.1093\/ckj\/sfaa117.","DOI":"10.1093\/ckj\/sfaa117"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"15. Ganz T, Nemeth E. Iron balance and the role of hepcidin in chronic kidney disease. Semin Nephrol. 2016;36(2):87-93. doi: 10.1016\/j.semnephrol.2016.02.001.","DOI":"10.1016\/j.semnephrol.2016.02.001"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"16. Del Vecchio L, Longhi S, Locatelli F. Safety concerns about intravenous iron therapy in patients with chronic kidney disease. Clin Kidney J. 2016;9(2):260-267. doi: 10.1093\/ckj\/sfv142.","DOI":"10.1093\/ckj\/sfv142"}],"container-title":["Polski Merkuriusz Lekarski"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T19:45:20Z","timestamp":1752263120000},"score":1,"resource":{"primary":{"URL":"https:\/\/polskimerkuriuszlekarski.pl\/wp-content\/uploads\/library\/PolMerkurLek2025i3.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":16,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025]]},"published-print":{"date-parts":[[2025,6]]}},"URL":"https:\/\/doi.org\/10.36740\/merkur202503113","archive":["Internet Archive"],"relation":{},"ISSN":["1426-9686"],"issn-type":[{"value":"1426-9686","type":"print"}],"subject":[],"published":{"date-parts":[[2025]]}}}